^
Association details:
| Biomarker: | FLT3-ITD mutation + FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Gilteritinib in relapsed FLT3-positive Acute Myeloid Leukemia after second allogeneic stem cell transplantation
Published date:
09/03/2020
Excerpt:
...a 63-year-old patient with relapsed FLT3-ITD AML...Second haploidentical HCT was performed in second CR after reinduction, this time with quizartinib maintenance. Hematologic relapse occurred again after 5 months. This time both FLT3-ITD and FLT3-TKD mutations were detectable.
